Building The Future Of Cancer Immunotherapy Through Allogeneic NK Cell Innovation

As the cell therapy space evolves beyond T cells, allogeneic natural killer (NK) cell therapies are emerging as a scalable and accessible approach in cancer immunotherapy. Cell & Gene's Chief Editor, Erin Harris, welcomed experts Raphael Ognar, President, CEO, and Co-Founder of NKILT Therapeutics, and Tracy Ryan, Co-Founder and Chief Communications Officer of NKore BioTherapeutics, for a detailed discussion exploring how their teams are advancing the field through distinct yet complementary strategies. The dynamic discussion highlighted the scientific innovation, technological differentiation, and patient-centered vision driving the next generation of allogeneic NK cell therapies, and why now is the critical moment to deepen research and exploration into novel NK platforms.